IMMX 8-K: Immix Biopharma ups ATM offering to $100M from $50M

Immix Biopharma ups ATM offering to $100M from $50M

Immix Biopharma, Inc.

Increased max aggregate offering price under ATM agreement from $50M to $100M.

Amendment updates registration statement to Form S-3 (File 333-292665).

Sales agent commission remains 3% of gross proceeds; $50K expense cap.

Company may sell shares at market prices from time to time; no minimum.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Immix Biopharma, Inc. amended Amendment No. 1 to At The Market Offering Agreement with Citizens JMP Securities, LLC valued at aggregate offering price of up to $100,000,000 in an at the market offering (effective 2026-03-25).

Action: amendment
Agreement: atm program
Counterparty: Citizens JMP Securities, LLC
Value: aggregate offering price of up to $100,000,000 in an at the market offering
Effective: 2026-03-25

Exact text from the filing

On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), through Citizens JMP Securities, LLC, as sales agent (the “Sales Agent”), having an aggregate offering price of up to $100,000,000 (the “Shares”) in an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).

View on SEC.gov